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The Use of Recombinant Activated Factor VII to Control Bleeding
during Repair of a Suprarenal Abdominal Aortic Aneurysm
C.-M. Wahlgren and J. Swedenborg
Department of Vascular Surgery, Karolinska Hospital, Stockholm, Sweden
Recombinant activated factor VII (rFVIIa) was first used to control bleeding in haemophilia patients. More recently, it has
been used to prevent severe bleeding in patients without pre-existing coagulopathy. We report a case where rFVIIa was used
to successfully control postoperative bleeding in a patient undergoing suprarenal abdominal aortic aneurysm (AAA) repair.
Introduction
Recombinant activated factor VII (rFVIIa) is mainly
used to control bleeding in haemophilia1 and other
haemostatic disorders, such as thrombocytopaenia,2
Glanzman's thrombasthenia,3 and disseminated intra-
vascular coagulation.4 More recently, rFVIIa has been
used in patients without pre-existing coagulopathy
to control peri-operative bleeding in trauma,5 heart
valve,6 liver7 and neurosurgery.8 The use of rFVIIa
has not so far been reported in patients undergoing
vascular surgery. Here, we report a case of a patient
undergoing reconstruction of a suprarenal AAA
where rFVIIa was used to successfully control post-
operative bleeding.
Case Report
A 62-year-old previously healthy man presented with
a 11 cm AAA originating above the celiac axis. On
admission, he was stable and laboratory indices,
including coagulation and liver function tests, were
normal. Through a thoraco-abdominal incision the
aorta was clamped above the celiac axis and an
oblique anastomosis fashioned with inclusion of the
celiac, superior mesenteric and right renal arteries.
The left renal artery was re-implanted into the
graft and the distal anastomosis was constructed
end-to-end to the distal aorta. Visceral arteries were
perfused with cold saline and the aortic clamp time
was approximately 60 min. Although adequate
haemostasis had been initially achieved, upon reper-
fusion diffuse `` non-surgical'' bleeding developed
which improved slightly after administration of tra-
nexamic acid, protamine sulfate and platelets. The
incision was then closed. A total of 22 units of fresh
frozen plasma (FFP) and 16 units of red blood cell
concentrate (RBC) had also been given.
The patient was unstable and was given more FFP,
RBC and platelets in the intensive care unit. The aPTT
time was prolonged and fibrinogen, platelets and anti-
thrombin levels were low. Following a single dose
(80 mg/kg) of intravenous rFVIIa (NovoSeven, Novo
Nordisk, Denmark) the patient became haemodynami-
cally stable and mounted an adequate diuresis. On the
first postoperative day the patient was taken back to
theatre and the retroperitoneal haematoma evacuated
without further bleeding. Liver enzymes were consid-
erably elevated but gradually normalised. Renal and
respiratory failure required intermittent dialysis and
continued ventilatory support after tracheotomy. The
patient's condition gradually improved and he was
later discharged for rehabilitation.
Discussion
Suprarenal and thoraco-abdominal aneurysm repair
is associated with increased bleeding due to impaired
haemostasis and possibly increased fibrinolysis
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secondary to hepatic and mesenteric ischaemia.9,10 At
the site of vascular injury, tissue factor (TF) forms a
complex with rFVIIa to initiate the generation of
thrombin. rFVIIa also binds to activated platelets
and by activating factor X induces thrombin forma-
tion independent of TF.11 In this patient, preoperative
haemostasis was normal and bleeding multifactorial:
blood transfusions, hypothermia, extensive surgical
dissection, hepatic and mesenteric ischaemia and
reperfusion. rFVIIa was given as a last resort after
conventional therapy had failed. In haemophilia
patients undergoing surgery, 90±110 mg/kg may be
given every 2 h for the first 24 post-operative hours.1
During heart valve surgery and liver transplantation
90 mg/kg is effective and safe6 and in trauma patients
the use of 120±212 mg/kg boluses have been
reported.5 In children 40 mg/kg has been used as sin-
gle or repeated doses at intervals of 6±7 h.12 Factor VII
is produced in the liver and has a plasma half-life of
4±6 h, which is shorter than most other coagulation
factors produced in the liver. There was laboratory
evidence of postoperative hepatic dysfunction prob-
ably due to ischaemia, which may well have led to
reduced FVIIa levels. There is a theoretical risk of
rFVIIa inducing thrombosis but this seems rare in
practice.13 In conclusion, recombinant FVIIa appears
to be a safe and effective treatment for bleeding dur-
ing vascular surgery when conventional therapies
have failed.
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